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In randomized studies evaluating treatments for tuberculosis (TB),
individuals are scheduled to be routinely evaluated for the presence of
TB using sputum cultures. One important endpoint in such studies is
the time of culture conversion, the first visit at which a patient’s spu-
tum culture is negative and remains negative. This article addresses
how to draw inference about treatment effects when sputum cultures
are intermittently missing on some patients. We discuss inference un-
der a novel benchmark assumption and under a class of assumptions
indexed by a treatment-specific sensitivity parameter that quantify
departures from the benchmark assumption. We motivate and illus-
trate our approach using data from a randomized trial comparing the
effectiveness of two treatments for adult TB patients in Brazil.
1. Introduction. In the design of randomized studies evaluating com-
peting treatments for patients with tuberculosis (TB), it is common to
culture sputum for the presence of TB at regularly scheduled clinic visits
over a specified time horizon. A primary goal in such studies is to estimate
the treatment-specific distribution of the time of culture conversion [Eu-
ropean Medicines Agency, Committee for Medicinal Products for Human
Use (2010)]. Culture conversion is said to have occurred for a patient at a
given visit if the sputum cultures for that visit and all subsequent visits are
negative. A key complication in the analysis arises when culture results are
missing at some visits, because the culture was contaminated, the patient
could not produce sputum, or the patient did not show up. Culture conver-
sion status at a given visit is unknown when from that visit onward at least
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one culture result is missing and all recorded culture results are negative.
For a given patient, the set of visits with unknown culture conversion status
is empty, or it consists of either a single visit or a set of consecutive visits. If
the set is not empty, the time of culture conversion will be known to lie in an
interval. The time may not be interval-censored in the classical sense, how-
ever, because certain data configurations may imply that culture conversion
cannot occur at certain visit times within the interval. To distinguish this
data structure from classic interval censoring, we refer to the set of feasible
times that are compatible with an individual’s data as the coarsening set.
The coarsening set can include a single point or a set of points.
The treatment-specific distribution of time of culture conversion is not
identified without untestable assumptions about the distribution of culture
conversion status within the coarsening sets. There are countless ways of
imposing such assumptions. The “worst-case” and “best-case” assumptions,
leading to bounds on the treatment-specific distribution of time of culture
conversion, are that the missing culture associated with the latest visit time
at which culture conversion status is unknown is positive and that the miss-
ing cultures associated with all visit times at which culture conversion status
is unknown are negative, respectively. In considering alternative assump-
tions, it is natural to condition on as much of the relevant data as possible.
In addition to conditioning on observed culture results, it is natural to condi-
tion on auxiliary factors that are associated with the unknown results inside
the coarsening set.
Most TB studies collect a key auxiliary time-varying variable. Sputum
specimens are also evaluated by smear, and the results of the smear may be
available when a culture is contaminated. Sputum smear is a less reliable
assessment of clinical tuberculosis than sputum culture. It relies on the vi-
sualization of the bacteria through a microscope after staining of sputum
with dyes that allows the microscopist to see so-called acid-fast TB bacte-
ria. Sensitivity of the sputum smear is about 0.5, but it can vary by staining
method used and clinical population. In contrast, sputum culture involves
breaking down the sputum (which is very viscous), decontaminating the
specimen to kill bacteria other than the mycobacteria, and inoculating it on
culture media where the bacilli can grow. Sensitivity of the sputum culture
is about 0.8–0.85 [American Thoracic Society (2000)]. Roughly 65% of those
with a positive culture are expected to have a positive smear, and nearly
100% of those with a positive smear are expected to have a positive culture
[American Thoracic Society (2000)].
Another important auxiliary variable is baseline cavitation status. Pa-
tients with pulmonary tuberculosis who have cavities seen on a chest ra-
diograph (cavitary tuberculosis) are more likely to have positive sputum
smears, as they harbor larger numbers of tubercle bacilli than patients with-
out cavities. It generally takes longer for patients with cavitary tuberculosis
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to convert their smears and cultures to negative during treatment, as they
have a larger bacterial load and the therapy must kill more organisms.
This article is motivated by data from a randomized TB study previously
analyzed by Conde et al. (2009).2 This phase II, double-blind, randomized
trial compared moxifloxacin vs. ethambutol in adults with smear-positive tu-
berculosis at baseline in a hospital in Rio de Janeiro, Brazil. All 170 patients
randomized (85 to each treatment arm) into the study were treated with a
background regimen of isoniazid, rifampicin and pyrazinamide. Patients with
a negative or contaminated smear or with drug-resistant Mycobacterium tu-
berculosis at baseline were excluded from the analysis, resulting in an analy-
sis sample of 74 and 72 patients in the moxifloxacin and ethambutol groups,
respectively. Treatment was scheduled to be given five days per week and
was to be directly observed by study personnel. Sputum specimens (sponta-
neous or induced) were scheduled to be collected at baseline and every week
for 8 weeks. The specimens were to be evaluated by both smear and cul-
ture testing. In this study, 55.4% and 62.5% of patients in the moxifloxacin
and ethambutol arms, respectively, had complete culture data through week
8. Time of culture conversion could be determined for 64.9% and 72.2%
of patients in these arms; the remaining patients had their time of culture
conversion coarsened.
In this article, we develop a method that estimates the treatment-specific
distribution of time of culture conversion under a class of assumptions on the
distribution of the coarsened time of culture conversion that conditions on all
of the relevant available data, including sputum cultures, sputum smears and
baseline data. Each assumption in the class is indexed by a treatment-specific
sensitivity-analysis parameter which quantifies the magnitude of discrepancy
from a specific benchmark assumption. In Section 2 we provide a preview
of our proposed method. In Section 3 we discuss our modeling assumptions
and approach to inference. Section 4 presents an analysis of data from the
Conde et al. (2009) study. The article concludes with a discussion.
2. Preview. Our approach starts by imposing nontestable assumptions
that identify the conditional distribution of time to culture conversion given
the data, for every data configuration for which time of culture conversion
is unknown. The crucial methodological challenge then is to make sensible
identifying assumptions. Because time of culture conversion is determined
by the results of sputum cultures, these assumptions ultimately identify the
visit-specific probabilities of the last positive sputum culture given the data.
2The data set provided to us differs slightly from that of Conde et al. (2009). There are
small differences in the number of observed cultures and the number of observed negative
cultures at each week. All analyses reported in this article are based on the data provided
to us.
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Lack of culture conversion at a given visit can be determined without full
knowledge of all subsequent results if the culture at that visit is positive or at
least one subsequent culture is observed to be positive. It turns out that with
“proper bookkeeping,” we can achieve identifiability by imposing assump-
tions that suffice to identify the distribution of time of culture conversion
but do not fully identify the joint distribution of results across visits. These
conditions identify the reverse-time conditional hazards of time of culture
conversion. This section illustrates these issues by means of an example.
The sputum culture data collected on one patient in the study illustrate
the coarsening structure of culture conversion status and the time of culture
conversion. The sputum culture data for this patient, whom we call Mary,
are displayed in the first line of Table 1; the associated culture conversion
statuses are displayed in line 2. Missing values are indicated by either R
or I, depending on whether they are relevant or irrelevant for establishing
culture conversion status. Mary has negative cultures at visits 4, 6, 7 and
8 and a positive culture at visit 2. She is a culture converter at visits 6, 7
and 8 (labeled “Y” in the second line), known not to be a culture converter
at visits 1 and 2 (labeled “N” in the second line) and has unknown culture
conversion status at visits 3, 4 and 5 (labeled U in the second line). First,
even though her culture status at visit 1 (labeled I in the first line) is missing,
it is irrelevant for determining whether she is a culture converter at that
visit, because she has a positive culture at visit 2 and therefore cannot be a
culture converter at visit 1. Second, missingness of cultures at visits 3 and
Table 1
Examples of patient data. − denotes negative culture, + denotes positive culture, U
denotes unknown, I denotes a missing culture result that is irrelevant for determining
culture conversion, and R denotes a missing culture result that is relevant for
determining culture conversion
Visit
Coarsening
setLine 1 2 3 4 5 6 7 8
1 Culture results I + R − R − − −
2 Conversion? N N U U U Y Y Y {3,4,6}
3 Culture results I + I − + − − −
4 Conversion? N N N N N Y Y Y {6}
5 Culture results I + R − − − − −
6 Conversion? N N U Y Y Y Y Y {3,4}
7 Culture results I + + − − − − −
8 Conversion? N N N Y Y Y Y Y {4}
9 Culture results I + − − − − − −
10 Conversion? N N Y Y Y Y Y Y {3}
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5 (labeled R in the first line) affects our ability to determine her culture
conversion status at visits 3, 4 and 5 because all cultures after visit 5 are
negative and the culture at visit 4 is also negative. So even though Mary has
a negative culture at visit 4, her culture conversion status is not known at
that visit. Third, the visits at which culture conversion status is unknown are
consecutive: the earliest and latest visits are 3 and 5, respectively. Finally,
the coarsening set for time of culture conversion comprises visits 3, 4 and 6.
This follows because if the culture at visit 5 were positive, then the time
of culture conversion would be visit 6, and if the culture at visit 5 were
negative, the time of culture conversion would be either visit 3 or visit 4,
depending on the result at visit 3.
To illustrate our approach for identifying the conditional distribution of
time of culture conversion given the data, consider subset A, the subset of
patients with the same observed data as Mary. Specifically, we must model
the probability that the cultures at visits 3 and 5 are both negative (in which
case the time of culture conversion is visit 3), the probability that the culture
at visit 3 is positive and the culture at visit 5 is negative (in which case the
time of culture conversion is visit 4), and the probability that the culture at
visit 5 is positive (in which case the time of culture conversion is visit 6).
In modeling these probabilities, it is natural to consider two chronological
factorizations. In forward time, we would need to model the probability of a
negative culture at visit 3, the conditional probability of a negative culture
at visit 5 given a negative culture at visit 3, and the conditional probability
of a negative culture at visit 5 given a positive culture at visit 3. In reverse
time, we would need to model (i) the probability of a positive culture at
visit 5 and (ii) the conditional probability of a positive culture at visit 3
given a negative culture at visit 5. We use this latter factorization as it
requires fewer modeling assumptions.
We first turn to the task of imposing assumptions that identify (i). Our
identifying assumption specifies that (i) is the same as the probability of a
positive culture at visit 5 among patients with the same data as in subset
A, with the exception that they have an observed culture at visit 5. The
observed culture results for these patients are depicted in lines 3 and 5.
These patients have observed culture conversion status as depicted in lines
4 and 6. The probability (i) is then assumed to be equal to the ratio of the
proportion of patients with observed results as in line 3 to the sum of the
proportions of patients with observed results as in lines 3 and 5.
Next, we turn to the task of imposing assumptions that identify (ii). Our
identifying assumption specifies that (ii) is the same as the probability of a
positive result at visit 3 among patients with the same pattern of observed
cultures as that in line 5, with the exception that they have an observed
culture at visit 3. The results of these patients are depicted in lines 7 and 9
with associated culture conversion status in lines 8 and 10. The probability
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(ii) is then assumed to be equal to the ratio of the proportion of patients
with observed cultures as in line 7 to the sum of the proportions of patients
with observed cultures as in lines 7 and 9.
In data sets of typical size, we will not be able to obtain reliable estimates
of the proportion of patients who have specific patterns of observed data
because of the curse of dimensionality. As a result, our inference will require
dimension-reduction assumptions. We will use fully parametric models for
the treatment-specific distributions of the data. These models are described
in Section 3.4.
In Section 3.3 we evaluate the sensitivity of our results to our identifying
assumptions by conducting inference under a class of exponential tilt devia-
tions from the assumed conditional probabilities for the unobserved culture
conversion status.
3. Formalization of the problem. Since we focus on inference about the
time of culture conversion, separately for each treatment arm, we consider,
until Section 3.5, only data from one arm and suppress notational depen-
dence on treatment assignment.
3.1. Data structure and notation. Let X denote baseline cavitation sta-
tus (1 for cavitation, 0 otherwise), Ck denote the indicator that the culture
is negative at visit k (1 for negative, 0 for positive) and Sk denote the indi-
cator that the smear is negative at visit k (1 for negative, 0 for positive). Let
M ck andM
s
k be the indicators that Ck and Sk are missing, respectively (1 for
missing, 0 for observed). The data recorded on an individual at visit k are a
realization of the random vector Ok = (M
c
k ,C
obs
k ,M
s
k , S
obs
k ), where C
obs
k =Ck
if Ck is observed and C
obs
k is empty otherwise and S
obs
k is defined likewise.
Let K denote the number of scheduled post-baseline visits. For any collec-
tion of random vectors {Wk}1≤k≤K , we use the notationW k = (W1, . . . ,Wk).
With this notation, the data recorded on an individual throughout the entire
study are a realization of the random vector O = (X,OK). It is useful to
denote the auxiliary data by V ≡ (X,M
s
K , S
obs
K ). For a random variable or
vector which is a function of O (e.g., V , L and R), we use lowercase notation
(e.g., v, l and r) to denote the realization associated with a given realization
o of O.
Define time of culture conversion T to be the earliest visit such that
sputum cultures are negative from that visit onward if such a visit exists
and T =K + 1 otherwise. With observed data O on a patient, T belongs
either to a set with a single visit time (in which case T is determined fromO)
or to a set with multiple visit times, not necessarily consecutive. We denote
the coarsening set where T is known to lie by T . Given O, T is determined
(i.e., the set T has one element) unless either:
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(i) the culture at visit K is missing, that is, M cK = 1, or
(ii) there exists a visit k <K with a missing culture, that is,M ck = 1, such
that all subsequent visits have sputum cultures that are either negative or
missing, that is, M cj = 1 or C
obs
j = 1 for j > k.
When either (i) or (ii) occurs, T will have multiple visit times. We denote
the lowest visit number in the set by L, which is the earliest visit k where the
sputum cultures are either missing or negative at and subsequent to visit k.
We denote the largest visit number in the set by R+1, where R=K if the
culture at visitK is missing (i.e.,M cK = 1) and R= k (k <K) if at visit k the
sputum culture is missing and at all subsequent visits the sputum cultures
are recorded and negative. The other times in the coarsening set include all
visit numbers k such that L< k <R+1 and M ck−1 = 1.
Formally, our inferential goal is to estimate the distribution of time of
culture conversion, that is, P [T = k] for k = 1, . . . ,K, based on n i.i.d. real-
izations of the vector O. We use the subscript i to denote data for the ith
individual.
In Section 3.2 we formally describe the identifying assumptions on which
our benchmark analysis relies. These assumptions were illustrated in Sec-
tion 2. The assumptions are “identifying” in the sense that once they are
imposed, we are able to express P [T = k] for k = 1, . . . ,Kas a function of
the distribution of the observed data O and, consequently, we can hope, to
estimate P [T = k] consistently. Subsequently, we propose models for depar-
tures from the benchmark assumptions that form the basis of our proposed
sensitivity analysis. Specifically, our sensitivity analysis consists of repeating
estimation of P [T = k] under various plausible departures from the bench-
mark assumptions.
Both our benchmark analysis and the models for our sensitivity analysis
rely on assumptions that identify the conditional distribution of T given the
observed data O. The marginal distribution of T is then obtained as the
mixture of the, now identified, conditional distribution of T given O mixed
over the distribution of the observed data O.
3.2. Benchmark identifying assumptions. To help guide our choice of
benchmark identifying assumptions, we first note that since P [T = k|O] = 0
if k /∈ T and P [T = k|O] = 1 if k ∈ T and |T |= 1, we only need assumptions
that suffice to identify P [T = k|O] when k ∈ T and |T |> 1. Thus, we proceed
in reverse order through the set T by postulating assumptions that identify
first P [T =R+1|O] and then sequentially P [T = k|T ≤ k,O], where k ∈ T ,
L< k <R+1. This iterative procedure results in assumptions that identify
P [T = k|O] for all k ∈ T . This follows because P [T =R+ 1|O] is identified
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and for k ∈ T , k < R+ 1, P [T = k|O] equals
P [T 6=R+ 1|O]
{ ∏
k<s<R+1
s∈T
P [T 6= s|T ≤ s,O]
}
P [T = k|T ≤ k,O].
To guide our choice of benchmark assumptions for identifying P [T = r+
1|O = o], we first note that given O= o the event T = r + 1 occurs if and
only if the culture at visit r is positive, that is, if Cr = 0. Our benchmark
assumption equates the unidentified probability P [T = r + 1|O = o] with
the identified probability that Cr = 0 in the subset of patients for which
O = o(r), where o(r) agrees with O in all its components except that the
culture at visit r is observed. Now we write the event O= o as the event
M cr = 1,M
c
r−1 =m
c
r−1,C
obs
r−1 = c
obs
r−1, V = v,M
c
j = 0,Cj = 1
(3.1)
for r+1≤ j ≤K,
we define the event O= o(r)as the event
M cr = 0,M
c
r−1 =m
c
r−1,C
obs
r−1 = c
obs
r−1, V = v,M
c
j = 0,Cj = 1
for r+1≤ j ≤K,
and we postulate that
P [T = r+1|O= o] = P [T = r+1|O= o(r)].(3.2)
Next we consider assumptions that identify P [T = k|T ≤ k,O = o] for
k ∈ T , l < k < r + 1. Once again, given (T ≤ k,O = o), the event T = k
occurs if and only if the culture result at visit k − 1 is positive, that is,
Ck−1 = 0. Because k ∈ T , l < k < r+ 1, we know that Ck−1 is missing, that
is,M ck−1 = 1. Our benchmark assumption in this case equates the probability
P [T = k|T ≤ k,O = o] with the identified probability that T = k (which
equates to the event Ck−1 = 0) in the subset of patients for whichO= o
(k−1),
where o(k−1) differs from the subset of patients with (T ≤ k,O= o) only in
that a sputum culture is observed at visit k − 1 and the event T ≤ k is
observed to occur (i.e., M cj = 0 and Cj = 1 for all k ≤ j ≤ K). Formally,
with the event O= o defined as in (3.1), we define the event O= o(k−1) as
the event
M ck−1 = 0,M
c
k−2 =m
c
k−2,C
obs
k−2 = c
obs
k−2, V = v,M
c
j = 0,Cj = 1
for k ≤ j ≤K
and assume
P [T = k|T ≤ k,O= o] = P [T = k|O= o(k−1)].(3.3)
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Patients in the subset defined by (T ≤ k,O= o) and subjects in the subset
O = o(k−1) have the same baseline factors and the same recorded history
of the auxiliary smear sputums throughout the study, as well as the same
recorded history of sputum cultures up to visit k− 2.
Finally, for a realization O= o where |T |> 1, P [T = l|T ≤ l,O= o] = 1.
3.3. Sensitivity analysis. The benchmark assumptions (3.2) and (3.3) are
untestable. For realizations O = o with |T | > 1, the following exponential
tilt model [Barndorff-Nielsen and Cox (1994)] expresses departures from our
benchmark assumptions:
P [T = r+1|O= o] =
P [T = r+1|O= o(r)] exp(α)
hr+1(o(r);α)
(3.4)
and for k ∈ T , l < k < r+1,
P [T = k|T ≤ k,O= o] =
P [T = k|O= o(k−1)] exp(α)
hk(o(k−1);α)
,(3.5)
where α is fixed and given and hk(o
(k−1);α) are normalizing constants equal
to E[exp{αI(T = k)}|O = o(k−1)] for k ∈ T , l < k ≤ r+ 1. Under this expo-
nential tilt model,
odds(P [T = r+1|O= o])
odds(P [T = r+ 1|O= o(r)])
=
odds(P [T = k|T ≤ k,O= o])
odds(P [T = k|O= o(k−1)])
= exp(α).
Thus, the magnitude of α quantifies the departure from our benchmark
assumptions. When α > 0 (< 0), P [T = r + 1|O = o] is greater (less) than
P [T = r+1|O= o(r)] and P [T = k|T ≤ k,O= o] is greater (less) than P [T =
k|O= o(k−1)]. As α→∞ (−∞), P [T = r+1|O= o] and P [T = k|T ≤ k,O=
o] go to one (zero). When α→∞ (−∞), the “worst-case” and “best-case”
bounds described in the Introduction are attained. α = 0 corresponds to
the benchmark assumption. To facilitate sensitivity analysis, our class of
models assumes that the departures from the benchmark assumption are
not time-specific.
3.4. Modeling. For specified α, estimation of the distribution of time of
culture conversion depends on our ability to estimate for each realization
O = o with |T | > 1, P [T = k|O = o(k−1)] for k ∈ T , l < k ≤ r + 1. How-
ever, in practice, these probabilities cannot be estimated nonparametrically.
Therefore, we use a parametric model for the law of the observed data O
given baseline cavitation status X . This model induces parametric models
for P [T = k|O= o(k−1)], k ∈ T , l < k ≤ r+1, that ultimately enable estima-
tion of P [T = k|O= o] by borrowing information across strata O= o(k−1).
We first recall that O= (X,OK), where Ok = (M
c
k ,C
obs
k ,M
s
k , S
obs
k ) are the
data available at visit k. We model the law of O by modeling the distribution
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of Ok given Ok−1 and X for all k = 1, . . . ,K, where O0 =∅. We use separate
logistic regression models for:
1. the probability of M ck = 1 given Ok−1 and X , that is,
logit{P [M ck = 1|Ok−1,X]}= a(k,Ok−1,X;γ
(a)),(3.6)
2. the probability that Cobsk = 1 given M
c
k = 0, Ok−1 and X ,that is,
logit{P [Cobsk = 1|M
c
k = 0,Ok−1,X]}= b(k,Ok−1,X;γ
(b)),(3.7)
3. the probability that M sk = 1 given M
c
k , C
obs
k , Ok−1 and X , that is,
logit{P [M sk = 1|M
c
k ,C
obs
k ,Ok−1,X]}= c(k,M
c
k ,C
obs
k ,Ok−1,X;γ
(c)),(3.8)
4. the probability that Sobsk = 1 given M
s
k = 0, M
c
k , C
obs
k , Ok−1 and X ,
that is,
logit{P [Sobsk = 1|M
s
k = 0,M
c
k ,C
obs
k ,Ok−1,X]}
(3.9)
= d(k,M ck ,C
obs
k ,Ok−1,X;γ
(d)),
where a(·), b(·), c(·) and d(·) are specified functions of their arguments and
γ(a), γ(b), γ(c) and γ(d) are unknown parameter vectors.
For the distributions in (3.7) and (3.9) we need not consider the cases
M ck = 1 and M
s
k = 1, respectively, because for such settings the conditional
distributions are degenerate (Cobsk is empty whenM
c
k = 1, and S
obs
k is empty
when M sk = 1).
3.5. Inference. Under models (3.6)–(3.9) we can express for all realiza-
tions O= o with |T |> 1 the conditional probability P [T = k|O= o(k−1)] for
k ∈ T , l < k ≤ r+1 as given functions of o(k−1) and γ = (γ(a), γ(b), γ(c), γ(d))
whose expressions, for the special case where the right-hand sides of (3.6)–
(3.9) only depend on Ok−1, are given in the Appendix. We denote this ex-
pression as P [T = k|O= o(k−1);γ]. Consequently, if we additionally assume
models (3.4) and (3.5), then we can express P [T = r+ 1|O= o] and P [T =
k|T ≤ k,O= o] (k ∈ T , l < k ≤ r) as given functions, P [T = r+1|O= o;γ;α]
and P [T = k|T ≤ k,O= o;γ;α] of o, γ and α.
The first step is to estimate γ using maximum likelihood; denote this
estimator by γ̂. This can be done using standard logistic regression software.
This step does not rely on specification of the sensitivity analysis parameter
α.
For fixed α, we estimate P [T = k] by P̂ [T = k;α] = 1
n
∑n
i=1 P̂ [Ti = k;α],
where P̂ [Ti = k;α] has one of four expressions depending on k and Oi. If
k /∈ Ti, then P̂ [Ti = k;α] = 0; if |Ti|= 1 and k ∈ Ti, then P̂ [Ti = k;α] = 1; if
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|Ti| > 1 and k = Ri + 1, then P̂ [Ti = k;α] = P [T = Ri + 1|O =Oi; γ̂;α]; if
|Ti|> 1 and k ∈ Ti, k <Ri + 1, then P̂ [Ti = k;α] equals
P [T 6=Ri +1|O=Oi; γ̂;α]
{ ∏
k<s<Ri+1
s∈Ti
P [T 6= s|T ≤ s,O=Oi; γ̂;α]
}
×P [T = k|T ≤ k,O=Oi; γ̂;α].
To compare the treatment-specific distributions of time to culture con-
version, one can estimate a common treatment effect over time. Toward this
end, one can use the logistic model for discrete survival data proposed by
Cox (1972). This model assumes that
hz(k)
1− hz(k)
= τk exp(βz), k = 1, . . . ,K, z = 0,1,
where z denotes treatment group, hz(k) = Pz[T = k|T ≥ k], and τ1, . . . , τK ≥ 0.
Here exp(β) is the ratio of the odds of first becoming a culture converter at
visit k given culture conversion at or after visit k, comparing moxifloxacin
with ethambutol.
To estimate the model parameters, one can use equally weighted minimum-
distance estimation [Newey and McFadden (1994)]. Specifically, for each
choice of αz (z = 0,1), we minimize the following objective function:
1∑
z=0
K∑
k=1
{
ĥz(k;αz)
1− ĥz(k;αz)
− τk exp(βz)
}2
with respect to τ1, . . . , τK ≥ 0 and β, where ĥz(k;αz) = P̂z[T = k|T ≥ k;αz].
For each choice of αz (z = 0,1), this method finds the “closest” fitting logistic
model to the “data:” {ĥz(k;αz) : k = 1, . . . ,K, z = 0,1}. Even if the model is
incorrectly specified, it can still be used to provide a valid test of the null
hypothesis of no treatment effect.
To estimate the standard error of our estimator, we propose the use of
nonparametric bootstrap.
4. Data analysis. Figure 1 displays the treatment-specific observed cul-
ture results, with rows denoting patients, columns denoting visits, black
indicating a positive culture, white indicating a negative culture and gray
indicating a missing culture. Figure 2 displays the treatment-specific coars-
ening sets for time of culture conversion, with white and gray indicating the
infeasible and feasible points, respectively.
By chance, the treatment groups were not balanced with respect to cavita-
tion status at baseline; 81.1% and 56.9% have cavitation in the moxifloxacin
and ethambutol arms, respectively. It is essential that our analysis adjust for
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Fig. 1. Treatment-specific observed culture results, with rows denoting patients, columns
denoting visits, black indicating a positive culture, white indicating a negative culture and
gray indicating a missing culture.
this key confounder. For each treatment group, we estimate the distribution
of time of culture conversion by a weighted average of cavitation-specific
distribution of time of culture conversion. The weights are taken to be the
marginal (i.e., not conditional on treatment arm) proportion of patients with
and without cavitation at baseline, respectively.
In our data analysis, we considered parsimonious models for the right-
hand sides of (3.6)–(3.9). Our choice of models was guided by substantive
considerations discussed with our scientist collaborators and by data ana-
lytic model-fitting techniques. Our final model assumed that the right-hand
sides of (3.6)–(3.9) depended only on Ok−1 = (M
c
k−1,C
obs
k−1,M
s
k−1, S
obs
k−1) (i.e.,
not on the other components of Ok−1), and the final model for (3.8) fur-
ther assumed that c(k,M ck ,C
obs
k ,Ok−1,X;γ
(c)) did not depend on Cobsk and
Cobsk−1. The latter assumption was imposed because missingness of a spu-
tum culture at visit k is highly predictive of missingness of smear sputums
at visits k and k − 1. In the Appendix we show that when the function
c(k,M ck ,C
obs
k ,Ok−1,X;γ
(c)) does not depend on Cobsk and C
obs
k−1 for all k,
TUBERCULOSIS STUDIES WITH MISSING SPUTUM DATA 13
Fig. 2. Treatment-specific coarsening sets, with rows denoting patients, columns denoting
visits, white indicating infeasible points and gray indicating feasible points.
P [T = k|O= o(k−1)] does not depend on c(k,M ck ,C
obs
k ,Ok−1,X;γ
(c)) for any
k, thus alleviating the need to further specify the function c(k,M ck ,C
obs
k ,
Ok−1,X;γ
(c)). In the remaining models, we “borrowed strength” across
treatment groups. Specifically, we assumed
az(k,Ok−1,X;γ
(a))
= γ
(a)
0,0,k + γ
(a)
0,1,kX + γ
(a)
1 I(k > 1)M
c
k−1 + γ
(a)
2 I(k > 1)(1−M
c
k−1)C
obs
k−1
+ γ
(a)
3 I(k > 1)M
s
k−1 + γ
(a)
4 I(k > 1)(1−M
s
k−1)S
obs
k−1+ γ
(a)
5 z,
bz(k,Ok−1,X;γ
(b))
= γ
(b)
0,k + γ
(b)
1 I(k > 1)M
c
k−1 + γ
(b)
2 I(k > 1)(1−M
c
k−1)C
obs
k−1
+ γ
(b)
3 I(k > 1)M
s
k−1 + γ
(b)
4 I(k > 1)(1−M
s
k−1)S
obs
k−1+ γ
(b)
5 z + γ
(b)
6 X,
dz(k,M
c
k ,C
obs
k ,Ok−1,X;γ
(d))
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= γ
(d)
0,k + γ
(d)
1 M
c
k + γ
(d)
2 (1−M
c
k)C
obs
k + γ
(d)
3 (1−M
c
k)C
obs
k X
+ γ
(d)
4 I(k > 1)M
c
k−1 + γ
(d)
5 I(k > 1)(1−M
c
k−1)C
obs
k−1
+ γ
(d)
6 I(k > 1)M
s
k−1 + γ
(d)
7 I(k > 1)(1−M
s
k−1)S
obs
k−1 + γ
(d)
8 z+ γ
(d)
9 X,
where the functions are subscripted by treatment z (z = 0 denotes ethamb-
utol, z = 1 denotes moxifloxacin).
Tables 2, 3 and 4 present estimates of the exponentiated parameters from
these models, along with 95% nonparametric bootstrap percentile confidence
intervals (based on 1000 resamples within treatment groups). In Table 2,
missingness of sputum culture (aOR = 4.45; 95% CI: 2.03–9.70) and miss-
ingness of smear (aOR = 3.51; 95% CI: 1.52–9.66) at a previous visit are
significant predictors of missingness of sputum culture at the next visit.
In Table 3, among patients with an observed sputum culture at visit k,
missingness of sputum culture (aOR = 4.00; 95% CI: 2.00–9.45), missing-
ness of a smear (aOR = 5.16; 95% CI: 1.67–22.47), a negative observed
culture (aOR = 6.37; 95% CI: 4.08–10.39) and a negative observed smear
(aOR = 3.93; 95% CI: 2.51–6.18) at visit k− 1, as well as assignment to the
moxifloxacin arm (aOR = 2.06; 95% CI: 1.46–3.19), are significant predictors
of a negative sputum culture at visit k. In Table 4, among patients with an
observed smear at visit k, missingness of smear (aOR = 3.66; 95% CI: 1.45–
14.53) and an observed negative smear (aOR = 6.99; 95% CI: 4.50–11.81)
at visit k − 1, as well as an observed negative sputum culture at visit k
(aOR = 10.73; 95% CI: 5.58–31.18), are significant predictors of a negative
smear at visit k.
Under our benchmark assumption, the estimated hazard ratio is 3.41 (95%
CI: [1.33,13.06]), indicating that patients treated with moxifloxacin have a
statistically significant shorter time of culture conversion than those treated
with ethambutol. Figure 3 displays a contour plot of the estimated odds
ratio as a function of α0 and α1. The region in white indicates combinations
of α0 and α1 where the lower bound of the 95% confidence interval is less
than 1. The gray region indicates combinations of α0 and α1 where the null
of no treatment difference is rejected in favor of moxifloxacin.
Inference would change relative to the benchmark assumption (circle
in Figure 3) if, say, α0 = 5.0, α1 = −3.0 (triangle in Figure 3) or α0 =
−4.0, α1 = −10.0 (square in Figure 3). At these combination of treatment-
specific sensitivity-analysis parameters, the estimated treatment effects are
2.19 (95% CI: 1.00–14.51) and 2.07 (95% CI: 0.97–5.38). To understand
whether these combinations are “far” from the benchmark assumption, con-
sider Figure 4. In the first row, we plot for each treatment group the esti-
mated distribution of time of culture conversion for these sensitivity-analysis
parameters (dashed and dotted lines) and the estimated distributions under
TUBERCULOSIS STUDIES WITH MISSING SPUTUM DATA 15
Table 2
(Exponentiated) parameter estimates and 95% confidence
intervals from the model for missingness of culture
results. See az(k,Ok−1,X;γ
(a)) for form of the model
Intercept Odds 95% CI
Wk 1 (exp(γ
(a)
0,0,1)) 0.14 [0.04,0.30]
Wk 2 (exp(γ
(a)
0,0,2)) 0.11 [0.03,0.24]
Wk 3 (exp(γ
(a)
0,0,3)) 0.03 [0.00,0.09]
Wk 4 (exp(γ
(a)
0,0,4)) 0.11 [0.03,0.25]
Wk 5 (exp(γ
(a)
0,0,5)) 0.07 [0.01,0.19]
Wk 6 (exp(γ
(a)
0,0,6)) 0.04 [0.00,0.12]
Wk 7 (exp(γ
(a)
0,0,7)) 0.05 [0.00,0.14]
Wk 8 (exp(γ
(a)
0,0,8)) 0.07 [0.01,0.18]
Predictor Odds ratio 95% CI
Wk 1*Cav (exp(γ
(a)
0,1,1)) 0.19 [0.00,0.90]
Wk 2*Cav (exp(γ
(a)
0,1,2)) 0.21 [0.00,0.87]
Wk 3*Cav (exp(γ
(a)
0,1,3)) 2.93 [0.81,∞]
†
Wk 4*Cav (exp(γ
(a)
0,1,4)) 0.38 [0.09,1.50]
Wk 5*Cav (exp(γ
(a)
0,1,5)) 1.63 [0.55,11.28]
Wk 6*Cav (exp(γ
(a)
0,1,6)) 1.39 [0.36,∞]
†
Wk 7*Cav (exp(γ
(a)
0,1,7)) 1.60 [0.47,∞]
†
Wk 8*Cav (exp(γ
(a)
0,1,8)) 1.63 [0.51,8.32]
I(k > 1)Mck−1 (exp(γ
(a)
1 )) 4.45 [2.03,9.70]
I(k > 1)(1−Mck−1)C
obs
k−1 (exp(γ
(a)
2 )) 0.89 [0.50,1.68]
I(k > 1)Msk−1 (exp(γ
(a)
3 )) 3.51 [1.52,9.66]
I(k > 1)(1−Msk−1)S
obs
k−1 (exp(γ
(a)
4 )) 1.28 [0.72,2.28]
Moxifloxacin (exp(γ
(a)
5 )) 1.07 [0.67,1.76]
†∞ here means a big number.
the benchmark assumption (solid lines). In the second row, we plot for each
treatment group the signed Kolmogorov distance between the estimated
distribution of time of culture conversion for given α and the estimated
distribution function of time of culture conversion under the benchmark
assumption. The signed Kolmogorov distance for treatment group z with
sensitivity analysis parameter αz equals F̂z(k
∗
z ;αz)− F̂z(k
∗
z ; 0), where
k∗z = argmax
k
|F̂z(k;αz)− F̂z(k; 0)|
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Table 3
(Exponentiated) parameter estimates and 95% confidence
intervals from the model for negative culture results. See
bz(k,Ok−1,X;γ
(b)) for form of the model
Intercept Odds 95% CI
Wk 1 (exp(γ
(b)
0,1)) 0.04 [0.02,0.08]
Wk 2 (exp(γ
(b)
0,2)) 0.03 [0.02,0.06]
Wk 3 (exp(γ
(b)
0,3)) 0.08 [0.04,0.14]
Wk 4 (exp(γ
(b)
0,4)) 0.10 [0.05,0.18]
Wk 5 (exp(γ
(b)
0,5)) 0.10 [0.05,0.17]
Wk 6 (exp(γ
(b)
0,6)) 0.24 [0.13,0.41]
Wk 7 (exp(γ
(b)
0,7)) 0.22 [0.12,0.40]
Wk 8 (exp(γ
(b)
0,8)) 0.49 [0.26,0.95]
Predictor Odds ratio 95% CI
I(k > 1)Mck−1 (exp(γ
(b)
1 )) 4.00 [2.00,9.45]
I(k > 1)(1−Mck−1)C
obs
k−1 (exp(γ
(b)
2 )) 6.37 [4.08,10.39]
I(k > 1)Msk−1 (exp(γ
(b)
3 )) 5.16 [1.67,22.47]
I(k > 1)(1−Msk−1)S
obs
k−1 (exp(γ
(b)
4 )) 3.93 [2.51,6.18]
Moxifloxacin (exp(γ
(b)
5 )) 2.06 [1.46,3.19]
Cavitation (exp(γ
(b)
6 )) 1.16 [0.81,1.75]
and F̂z(k;αz) is the estimated cumulative distribution function. When α0 =
5.0 and α1 =−3.0, the signed distances for the ethambutol and moxifloxacin
arms are 0.047 and −0.11, the latter being a fairly sizable difference (for the
moxifloxacin arm, the estimated probability of culture conversion by visit 5
is 49.6% under the benchmark assumption and 38.2% when α1 = −3.0).
Further, the distances are of opposite signs (i.e., the bias differs between
arms). When we look at other combinations of sensitivity-analysis parame-
ters where the null hypothesis is not rejected, the sensitivity-analysis param-
eter for the moxifloxacin arm is less than or equal to −3.0 and the associ-
ated signed distances are at least as extreme as −0.11. When α0 =−4.0 and
α1 = −10.0, the signed distances are −0.11 and −0.16 for the ethambutol
and moxifloxacin arms, respectively. Here the signs are in the same direc-
tion, but the choice of sensitivity-analysis parameters yields results that are
very close to the worst-case bounds that assume that all missing cultures are
positive. From a clinical perspective, inferences relative to the benchmark
assumption are fairly robust.
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Table 4
(Exponentiated) parameter estimates and 95% confidence
intervals from the model for smear results. See
dz(k,M
c
k ,C
obs
k ,Ok−1,X;γ
(d)) for form of the model
Intercept Odds 95% CI
Wk 1 (exp(γ
(d)
0,1)) 0.25 [0.13,0.42]
Wk 2 (exp(γ
(d)
0,2)) 0.34 [0.20,0.56]
Wk 3 (exp(γ
(d)
0,3)) 0.35 [0.21,0.58]
Wk 4 (exp(γ
(d)
0,4)) 0.21 [0.11,0.37]
Wk 5 (exp(γ
(d)
0,5)) 0.35 [0.19,0.65]
Wk 6 (exp(γ
(d)
0,6)) 0.20 [0.10,0.39]
Wk 7 (exp(γ
(d)
0,7)) 0.23 [0.12,0.43]
Wk 8 (exp(γ
(d)
0,8)) 0.24 [0.11,0.53]
Predictor Odds ratio 95% CI
Mck (exp(γ
(d)
1 )) 1.24 [0.61,2.61]
(1−Mck)C
obs
k (exp(γ
(d)
2 )) 10.73 [5.58,31.18]
(1−Mck)C
obs
k ·Cav (exp(γ
(d)
3 )) 0.46 [0.16,1.04]
I(k > 1)Mck−1 (exp(γ
(d)
4 )) 1.52 [0.66,3.46]
I(k > 1)(1−Mck−1)C
obs
k−1 (exp(γ
(d)
5 )) 1.44 [0.92,2.38]
I(k > 1)Msk−1 (exp(γ
(d)
6 )) 3.66 [1.45,14.53]
I(k > 1)(1−Msk−1)S
obs
k−1 (exp(γ
(d)
7 )) 6.99 [4.50,11.81]
Moxifloxacin (exp(γ
(d)
8 )) 0.97 [0.63,1.48]
Cavitation (exp(γ
(d)
9 )) 1.18 [0.75,1.85]
5. Discussion. Conde et al. (2009) did not compare the treatments with
respect to time of culture conversion. Rather, they compared the treatment-
specific probabilities of being a culture converter at or prior to week 8,
which is equivalent to having a negative culture at week 8. They used two
methods. The primary method assumed that all missing cultures at week 8
were positive (moxifloxacin: 77.0%; ethambutol: 62.5%; difference: 14.5 per-
centage points, 95% CI [−0.0 percentage points, 29.0 percentage points]);
the secondary method excluded patients who were missing their week 8 cul-
ture, assuming that the missing cultures were missing completely at random
(moxifloxacin: 90.5%; ethambutol: 73.8%; difference: 16.7 percentage points,
95% CI [3.4 percentage points, 30.4 percentage points]). The former analy-
sis was not statistically significant, whereas the latter analysis did suggest a
statistically significant treatment effect in favor of moxifloxacin. Their anal-
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Fig. 3. Contour plot of the estimated ratio of the odds of first becoming a culture con-
verter at visit k given culture conversion at or after visit k, comparing moxifloxacin vs.
ethambutol as a function of the sensitivity-analysis parameters α0 and α1. The region in
white indicates combinations of α0 and α1 where the lower bound of the 95% confidence
interval is less than 1. The gray region indicates combinations of α0 and α1 where the
null of no treatment difference is rejected in favor of moxifloxacin. The circle denotes the
benchmark assumption (α0 = 0.0, α1 = 0.0). The triangle (α0 = 5, α1 = −3) and square
(α0 =−4, α1 =−10) denote two combinations discussed in the text.
ysis made no attempt to account for imbalance in baseline cavitation status
between treatment groups.
It is tempting to think that this problem can be addressed by simply ana-
lyzing the culture results using standard statistical methods for longitudinal
binary data (e.g., marginal models and generalized linear mixed models).
A marginal model, fit using generalized estimating equations, identifies, un-
der the assumption that the culture results are missing completely at ran-
dom, the probability of a negative culture at each visit k; it does not admit
identification of the distribution of time of culture conversion. In contrast,
a generalized linear mixed model is a fully parametric model for the joint
distribution of the culture results and, under the missing at random assump-
tion, admits identification of the distribution of time of culture conversion.
However, the modeling assumptions are too strong, as they essentially allow
the “imputation” of missing culture results that are not needed to identify
the distribution of interest (e.g., the imputation of missing cultures that are
followed by positive cultures). Further, the model induces testable restric-
tions, and, as discussed by Robins and Gill (1997), the missing-at-random
assumption is often unrealistic in follow-up studies with intermittent missing
data. Nonetheless, we fit a logistic-normal generalized linear mixed model
to the culture data with fixed effects for time, treatment and cavitation
and a random intercept. Using the model, we estimated, within levels of
time, treatment and cavitation, the induced probability of a negative cul-
ture among those with missing cultures. Many of the estimated probabilities
were either greater than 1 or less than 0, suggesting inadequate model fit.
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Fig. 4. First row: Treatment-specific estimated distribution of time of culture conversion
for the benchmark and alternative sensitivity-analysis parameters considered in the text.
Second row: For each treatment group, the signed Kolmogorov distance between the esti-
mated distribution of time of culture conversion for given α and the estimated distribution
function of time of culture conversion under the benchmark assumption.
An alternative way of analyzing the culture data would treat the data
for each patient as the set of times of culture conversion that are consistent
with their observed culture data (i.e., the coarsening set) and estimate the
distribution of time to culture conversion under the coarsening-at-random
(CAR) assumption [Gill, Van der Laan and Robins (1997), Heitjan (1993,
1994), Heitjan and Rubin (1991)]. This assumption states that the coars-
ening process provides no information about the time of culture conversion
beyond conveying that the true event time is in the observed coarsening
set. Under CAR, the coarsening process is “ignorable” (i.e.
20 D. SCHARFSTEIN ET AL.
the likelihood for the observed data). Under this assumption, the estimated
value of β is 2.92 (95% CI: 1.09–11.95). The result is statistically significant
and favors moxifloxacin.
We have assumed, as in most analyses of culture conversion data, that the
test results are measured without error. We know that this is not correct.
It would be interesting to use known information about the sensitivity and
specificity of the culture and smear procedures to learn about the “true”
distribution of time of culture conversion. This will be the subject of future
research.
In our analysis, we did not have access to the reasons for missingness. We
know them to be a combination of three main sources: culture contamina-
tion, inability to produce sputum and skipped clinic visits. For the former
two reasons, the culture results are more likely to be negative. Contamina-
tion of sputum cultures with bacteria from the mouth and airways occurs
in 2–10% of specimens and varies by laboratory. Patients producing smaller
amounts of sputum that is mixed with saliva are more likely to have con-
tamination; therefore, patients who have responded to therapy (i.e., have
negative cultures) and no longer are producing large volumes of sputum
may be more likely to have a contaminated specimen. Patients with treated
tuberculosis who can no longer produce sputum are also likely to have re-
sponded to therapy and have negative cultures. If most of the missing data
are due to these two causes, it is not so surprising that the results of the
benchmark analysis are so close to the “best-case” bounds.
In summary, we introduced a novel benchmark assumption that allows
us to “learn” about the distribution of just those unknown culture results
that are absolutely necessary to identify the distribution of time of culture
conversion by “borrowing strength” from patients who are as similar as pos-
sible (with respect to baseline cavitation status, treatment assignment, and
observed culture and sputum results) and on whom the distribution of these
culture results is identified. We evaluated the sensitivity of inferences to our
benchmark assumption by embedding it in a class of model assumptions in-
dexed by sensitivity-analysis parameters. Although the sensitivity-analysis
parameters themselves are not scientifically interpretable, the induced dis-
tribution of time of culture conversion (and functionals thereof) can be es-
timated and compared with that under the benchmark assumption. If the
differences are judged “large” by scientific experts, we hope that they will
comment on the fragility or robustness of the benchmark inference. Except
in rare settings where the treatment effects are so dramatic or missing data
are so minor, we see no alternatives to sensitivity analysis aided by scientific
judgement.
The ideas described in this article can be applied to any study design
in which an enrolled subject is expected to undergo a fixed sequence of
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“pass/fail” tests, one or more test results may be missing, and interest fo-
cuses on estimating the distribution of the earliest test at which a subject
“passes” (“fails”) that and all subsequent tests. For example, the methods
described here would be highly relevant for analyzing studies of treatment
of hepatitis C virus (HCV) infection with antiviral therapy, particularly in
light of new and highly active direct-acting agents. In these studies, patients
are typically treated for 24 or 48 weeks, with HCV viral load measured re-
peatedly during and after treatment [see, e.g., Nelson et al. (2012)]. Here
a “pass” denotes HCV viral load below the limit of detection. Addition-
ally, the methods can be easily adapted to address the classic discrete-time
interval-censoring problem where each coarsening set consists of either one
time point or a collection of contiguous time points.
APPENDIX
A straightforward application of the law of total probability entails that
under models (3.6)–(3.9),
P [T = k|O= o(k−1);γ] =
gk−1(0,Ok,X;γ)∑1
y=0 gk−1(y,Ok,X;γ)
,
where
gk(y,Ok+1,X;γ) = (1− expit{a(k+ 1,Ok(0, y),X;γ
(a))})
× expit{b(k,Ok−1,X;γ
(b))}y
× (1− expit{b(k,Ok−1,X;γ
(b))})(1−y)
× expit{b(k+1,Ok(0, y),X;γ
(b))}
× (1− expit{c(k,0, y,Ok−1,X;γ
(c))})(1−M
s
k
)
× expit{c(k,0, y,Ok−1,X;γ
(c))}M
s
k
× (1− expit{c(k+1,0,1,Ok(0, y),X;γ
(c))})(1−M
s
k+1)
× expit{c(k+1,0,1,Ok(0, y),X;γ
(c))}M
s
k+1
× (1− expit{d(k,0, y,Ok−1,X;γ
(d))})(1−Sk)
× expit{d(k,0, y,Ok−1,X;γ
(d))}Sk
× (1− expit{d(k+1,0,1,Ok(0, y),X;γ
(d))})(1−Sk+1)
× expit{d(k+1,0,1,Ok(0, y),X;γ
(d))}Sk+1
and Ok(0, y) represents observed data at visit k with M
c
k set to 0 and Ck
set to y.
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If c(j,M cj ,C
obs
j ,Oj−1,X;γ
(c)) does not depend on Cobsj and C
obs
j−1 for all
j, then P [T = k|O = o(k−1);γ] does not depend on γ(c).
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